Management and Treatment of Brugada Syndrome

Introduction to Brugada Syndrome Management

The European Society of Cardiology recommends that all patients diagnosed with Brugada syndrome must implement strict lifestyle changes to prevent sudden cardiac death, regardless of symptom status 1, 2, 3
Patients with Brugada syndrome should avoid all drugs that induce ST-segment elevation in right precordial leads, including sodium channel blockers, certain psychotropic agents, and specific anesthetic drugs, as recommended by the European Heart Journal 1, 4, 5

The European Heart Journal suggests that patients with Brugada syndrome should avoid excessive alcohol intake and large meals, as these are known triggers for ventricular fibrillation 1, 2, 3
The European Society of Cardiology recommends treating any fever immediately and aggressively with antipyretics, as fever is a critical trigger that can precipitate cardiac arrest and accounts for 27% of life-threatening arrhythmic events 1, 4

The European Heart Journal states that ICD implantation is the only treatment proven to prevent sudden cardiac death in Brugada syndrome and is mandatory for high-risk patients, including survivors of aborted cardiac arrest and those with documented spontaneous sustained ventricular tachycardia 1, 2, 3, 6
The American College of Cardiology recommends ICD implantation for patients with Brugada syndrome who have a history of syncope presumed arrhythmic, with an annual event rate of 3.2% 1, 2, 4, 5

The European Heart Journal suggests that quinidine should be considered as first-line therapy for patients who refuse ICD, have contraindications, or experience electrical storms, with a Class IIa indication for patients who qualify for ICD but refuse or have contraindications 1, 2, 6
Quinidine reduces ventricular fibrillation inducibility during programmed ventricular stimulation, according to the European Heart Journal 1, 6

The European Society of Cardiology recommends using a risk stratification algorithm to determine management intensity, with the highest risk category (13.5% annual event rate) including cardiac arrest survivors or documented sustained VT, who should receive ICD implantation 1, 5
The American Heart Association suggests that patients with spontaneous type 1 ECG pattern and syncope presumed arrhythmic should be considered high risk (3.2% annual event rate) and should strongly consider ICD implantation 1, 4, 5

The European Heart Journal states that males are affected 8-10 times more frequently than females, with a mean age of ventricular fibrillation at 41 ± 15 years, and that prevalence is higher in Southeast Asia (1 in 1,000 to 1 in 10,000) 1
Arrhythmias typically occur during rest or sleep, according to the European Heart Journal 1, 2